Wolfe Research Initiates Coverage On LB Pharmaceuticals with Outperform Rating, Announces Price Target of $45

Benzinga Newsdesk www.benzinga.com Positive 83.1%

Neg 0% Neu 0% Pos 83.1%

Wolfe Research analyst Rudy Li initiates coverage on LB Pharmaceuticals (NASDAQ:LBRX) with a Outperform rating and announces Price Target of $45.